glp-1/gip peptide Role of a Dual Glucose-Dependent Insulinotropic (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment GLP-1 and GIP receptor signaling

In 2024 Wegovy was the first drug approved by the FDA to treat cardiovascular disease in people with obesity

8 May 2025

Jeffrey Egler, Nooms chief medical officer, noting more than 10,000 people have signed up

Dual GIPGLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume 12, 19731985

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride

If youve spent years feeling like your brain has a background narrative of constant thoughts about your next meal, what you should eat, what you shouldnt have eaten, how to fix tomorrow, you know that noise is exhausting